Actimis currently has two small molecule lead compounds at different stages of pre-clinical development for respiratory and inflammatory diseases. Both programs center around highly-validated molecular entities on leukocytes that are the primary cell types activated in the allergic response — eosinophils, basophils, mast cells and lymphocytes of the T helper type 2 lineage. The targets are 7-transmembrane G-protein coupled receptors (GPCRs) whose activation is linked to the migration and activation of the cells in question. Having previously screened and optimized small molecule antagonists against these targets according to rigorous industry standards, Actimis scientists are now continuing to progress these product candidates through pre-clinical IND-enabling analyses.

Actimis also has three proprietary genomics targets in early discovery stages. One of these genes, a kinase, has been discovered following a microarray analysis of human lung tissue from patients with chronic obstructive lung disorder (COPD) and preliminary analyses have revealed a significant role for this gene in the production of highly relevant inflammatory mediators, and neutrophilic inflammation — a hallmark of the disease. This target will undergo further discovery analyses and testing to identify a small molecule therapeutic for COPD. Two other proprietary targets are GPCRs highly expressed in the lung and linked to pro-inflammatory activation and will continue to be developed with a goal of identifying small molecule antagonists for respiratory and inflammatory diseases.